Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR ALK-Abelló A/S (4AJ0.F) Follow Compare 20.54 -0.52 (-2.47%) At close: February 27 at 6:37:12 PM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 4AJ0.F 1D 5D -5.43% 1M 0.10% 3M -3.93% 6M -15.19% YTD -3.20% 1Y 18.39% 5Y 68.22% All 374.36% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 4AJ0.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations FDA approves ODACTRA® for the treatment of house dust mite allergy in young children Alk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Annual General Meeting in ALK-Abelló A/S on 13 March 2025 Annual report 2024: ALK delivers 15% sales growth with profits up 65% Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025 ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system 3 Stocks Estimated To Be Trading At Discounts Of 26% To 44% 3 Stocks That May Be Trading Below Estimated Value ALK – Financial calendar for the 2025 financial year Positive results advance peanut tablet to phase II development ACARIZAX® approved in Europe for treatment of young children